

27 September 2019

NZX Announcement

RESIGNATION OF CHIEF EXECUTIVE OFFICER

TruScreen advises that Mr Martin Dillon has resigned as the Chief Executive Officer of the Company and will leave on completion of his notice period in late December 2019.

Martin has been with Truscreen since January 2014 and has been a key member of the TruScreen executive team which was responsible for driving further development of the TruScreen device, overseeing the successful growth of our major distributors in China, Vietnam and Mexico and developing new markets, including India, Zimbabwe and Russia.

Martin will continue his association with Truscreen as a consultant post resignation.

The Company will commence a recruitment process for a replacement Chief Executive to lead the Company forward into its next phase of its development.

Tony Ho, Chairman commented, *“On behalf of the Board I would like to thank Martin for his significant contribution to the growth and development of TruScreen over the last 5 years. We wish him well as he returns to his previous successful marketing career in Sports management.”*

Anthony Ho
Chairman

For more information visit www.TruScreen.com or contact:

TruScreen

Anthony Ho
Chairman

tonyho@truscreen.com

TruScreen

Guy Robertson
CFO

guyrobertson@truscreen.com

Investors

Investor Relations
Phone: +61 2 9237 2801

TruScreen@we-buchan.com

About TruScreen:

Watch our video on TruScreen: <http://truscreen.com/truscreen-the-company/truscreen-ultra-video/>

TruScreen is a Cervical Cancer Screening Device which offers the latest technology in cervical screening, providing real-time, accurate detection of pre-cancerous and cancerous cervical cells to help improve the health and well-being of women around the world. TruScreen's real-time cervical cancer technology utilises a digital wand which is placed on the surface of the cervix to measure electrical and optical signals from the surrounding tissues. A sophisticated proprietary algorithm framework is utilised to detect pre-cancerous change, or cervical intraepithelial neoplasia (CIN), by optical and electrical measurement of cervical tissue.



TruScreen offers an alternative approach to cervical screening, resolving many of the ongoing issues with Pap tests including failed samples, poor patient follow up, patient discomfort and the need for supporting laboratory infrastructures. As such, TruScreen target market is developing countries where no large scale cervical cancer screening programs and infrastructure are in place, such as; China, Mexico, Africa, Russia and India. TruScreen's cervical cancer screening device is EC certified for use throughout Europe and CFDA approved for sale in China. Truscreen gained recognition from Global NGO's WHO and Unitaidd in a joint Cervical Cancer Technology Landscape released at the 72nd World Health Assembly.

For more information, visit our website at www.truscreen.com